Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes.

Next Previous
X
Search
Trial Profile

An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Hypereosinophilic syndrome
  • Focus Adverse reactions
  • Sponsors GSK

    • Most Recent Events

    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 09 May 2016 Status changed from completed to discontinued as the subjects eligible to continue mepolizumab treatment were transferred into the compassionate programme (MHE104317).
    • 04 Aug 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top